These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23443308)

  • 21. Drug rechallenge and treatment beyond progression--implications for drug resistance.
    Kuczynski EA; Sargent DJ; Grothey A; Kerbel RS
    Nat Rev Clin Oncol; 2013 Oct; 10(10):571-87. PubMed ID: 23999218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New targets for cancer chemotherapy.
    Murgo AJ; Dancey J; Eckhardt SG; Hidalgo M; Arbuck SG; Zerivitz K; Blaylock BA
    Cancer Chemother Biol Response Modif; 2002; 20():239-72. PubMed ID: 12703208
    [No Abstract]   [Full Text] [Related]  

  • 23. Developing drugs that do not cause tumor regression.
    Stadler W
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
    [No Abstract]   [Full Text] [Related]  

  • 24. Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting.
    Corti A; Franzini M; Paolicchi A; Pompella A
    Anticancer Res; 2010 Apr; 30(4):1169-81. PubMed ID: 20530424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticancer therapy-induced adverse events: practicing damage control.
    Lacouture ME; Lenihan D; Wu S
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S1-3. PubMed ID: 22409299
    [No Abstract]   [Full Text] [Related]  

  • 26. Overview of tumor cell chemoresistance mechanisms.
    Gatti L; Zunino F
    Methods Mol Med; 2005; 111():127-48. PubMed ID: 15911977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanotechnology applied to overcome tumor drug resistance.
    Gao Z; Zhang L; Sun Y
    J Control Release; 2012 Aug; 162(1):45-55. PubMed ID: 22698943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bibliography. Current world literature. Therapeutic modalities.
    Curr Opin Oncol; 2001 Nov; 13(6):B172-92. PubMed ID: 11708263
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
    Huang S; Houghton PJ
    Curr Opin Investig Drugs; 2002 Feb; 3(2):295-304. PubMed ID: 12020063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer robustness: tumour tactics.
    Kitano H
    Nature; 2003 Nov; 426(6963):125. PubMed ID: 14614483
    [No Abstract]   [Full Text] [Related]  

  • 31. Chemotherapy sensitivity and response assays: are the ASCO guidelines for clinical trial design too restrictive?
    Wieand HS
    J Clin Oncol; 2005 May; 23(15):3643-4; author reply 3646-8. PubMed ID: 15908687
    [No Abstract]   [Full Text] [Related]  

  • 32. Resisting a fundamentalist policy.
    Castro M
    J Clin Oncol; 2005 May; 23(15):3645-6; author reply 3646-8. PubMed ID: 15908688
    [No Abstract]   [Full Text] [Related]  

  • 33. Preface: National Cancer Act.
    Smalley KS
    Adv Pharmacol; 2012; 65():xi-xiii. PubMed ID: 22959037
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy.
    Boldrini JL; Costa MI
    IMA J Math Appl Med Biol; 2000 Mar; 17(1):33-51. PubMed ID: 10757031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental and clinical effects of anticoagulants on cancer progression.
    Van Noorden CJ; van Sluis GL; Spek CA
    Thromb Res; 2010 Apr; 125 Suppl 2():S77-9. PubMed ID: 20434011
    [No Abstract]   [Full Text] [Related]  

  • 36. Haplotypes of XRCC1 and survival outcome in patients with metastatic breast cancer.
    Bewick MA; Conlon MS; Lafrenie RM
    Breast Cancer Res Treat; 2009 Oct; 117(3):667-9. PubMed ID: 19127428
    [No Abstract]   [Full Text] [Related]  

  • 37. Resisting resistance.
    Ewan S
    Drug Discov Today; 2005 Aug; 10(15):1015. PubMed ID: 16055015
    [No Abstract]   [Full Text] [Related]  

  • 38. Editorial.
    Pharmacol Res; 2017 Dec; 126():1. PubMed ID: 29153292
    [No Abstract]   [Full Text] [Related]  

  • 39. In vitro drug resistance versus chemosensitivity: two sides of different coins.
    Fruehauf JP; Alberts DS
    J Clin Oncol; 2005 May; 23(15):3641-3; author reply 3646-8. PubMed ID: 15908686
    [No Abstract]   [Full Text] [Related]  

  • 40. [Multicenter clinical trial of the antitumor drug Dioxadet (phase II)].
    Gershanovich ML; Filov VA; Kotova DG; Stukov AN; Sokolov IuN; Ivin BA
    Vopr Onkol; 1998; 44(2):216-20. PubMed ID: 9615831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.